@article{TLCR28796,
author = {Yiqing Huang and Robert J. Walsh and Ross A. Soo},
title = {The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {5},
year = {2019},
keywords = {},
abstract = {Immune checkpoint inhibitors (ICIs) have altered the treatment landscape of advanced non-small cell lung cancer (NSCLC) that lack driver mutations. In 2016, Reck and colleagues first reported the superiority of pembrolizumab versus chemotherapy in advanced NSCLC with PD-L1 tumour proportion score (TPS) ≥50% (KEYNOTE 024) (1).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/28796}
}